Skip to main content
. 2023 Mar 6;9:81. doi: 10.1038/s41420-023-01383-4

Fig. 4. RSL3+iron impairs PCa growth in vivo.

Fig. 4

A In vivo growth of subcutaneous TRAMP-C2 tumors treated i.p. with iron dextran 200 mg/kg twice/week, RSL3 40 mg/kg twice/week or RSL3 + iron and compared with untreated (NT) ones. B Prussian Blue staining (blue dots) and total iron content assay on tumor samples. Data are expressed as % fold change over the not treated (NT). C qPCR of ferroptosis related genes in tumor samples. Data are expressed as % fold change over the not treated (NT). D Immunohistochemistry and quantification of immune populations (CD3, FOXP3 and Ly6G markers) in tumor samples expressed as positive cells/mm2. Data are the mean ± SEM of 8–10 tumors/group. *p < 0.05, ***p < 0.001, #p < 0.0001 refers to each group vs NT group. Scale bar = 100 μm.